RSV vaccine booster for older adults
Treatments studied
Part of Infections clinical trials.
This trial tests a booster dose of an experimental RSV vaccine (SCB-1019T) in healthy adults aged 60-85 who have already received the approved RSV vaccine AREXVY. The goal is to see if the booster is safe and boosts your immune system.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Aged 60 to 85 years old
- Previously received the AREXVY RSV vaccine
- In good general health (stable medical conditions are okay)
- No fever or major illness on vaccination day
- No history of severe allergic reaction to vaccines
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how well an RSV vaccine (Arexvy) works in people whose immune systems are weakened by certain cancers, autoimmune diseases, or treatments. It aims to see if the vaccine can protect these vulnerable groups from respiratory infections.
This study tests an RSV vaccine to see if it is safe and helps your immune system fight the virus. It's for older adults who are generally healthy, and it may help protect you from severe RSV illness.
This trial tests a new RSV vaccine for people aged 60 and above. RSV is a common virus that can cause serious breathing problems in older adults. The study will see if the vaccine is safe and helps protect you from RSV.
This trial studies whether giving a booster dose of the RSV vaccine (Abrysvo) is safe and effective for adults with weakened immune systems. It includes people who have never had an RSV vaccine and those who had one or two doses in the past.
This study tests an RSV vaccine in people with weakened immune systems (like transplant recipients) and in older adults. It aims to see how well the vaccine boosts protection against RSV, a common respiratory virus.
This trial tests an experimental vaccine to protect older adults against respiratory syncytial virus (RSV), a common virus that can cause serious lung infections. It looks at whether the vaccine is safe and how well it boosts immunity. If you are healthy and over 60, you might be able to join.
Hear when a new RSV Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.